Articles tagged with Tuberculosis
Researchers have identified a substance produced by the tuberculosis bacterium that triggers an immune response, suggesting it could enhance vaccine effectiveness. The substance, combined with vaccines, may push the body's immune system in the right direction to fight tuberculosis and other microbial infections.
A new study by UCSF researchers found a significant decline in TB rates in San Francisco from 1992 to 1997, attributing it to intensified control measures. The study used molecular epidemiology to track the disease and determine the effect of interventions on transmission rates.
A new report by Johns Hopkins Medicine highlights the inadequate tuberculosis control programs in developing countries, particularly in sub-Saharan Africa where HIV infection rates are high. The report recommends improved screening, treatment, and integration of TB and HIV care to reduce transmission.
A new study suggests that crowded urban buses in Buenos Aires could be responsible for 30% of new tuberculosis cases. Researchers found that bus travel increases the risk of infection due to overcrowding and poor ventilation, posing a significant public health threat.
Researchers developed a code using first two letters of last name, first name, month of birth, year of birth, and sex. This allowed them to identify 124 HMO members with active TB listed in the state's registry but not known by their HMO
The development of a new vaccine is crucial to effectively eliminate tuberculosis (TB) as a global health problem. The ideal vaccine should prevent new infection, protect those already infected from developing active disease, and prevent reinfection in previously infected individuals.
Scientists have identified KasA, a critical protein in bacterial growth, as the target of isoniazid. This discovery enables the development of new anti-TB drugs and fast-screening assays to combat antibiotic-resistant strains.
Scientists have developed a new TB vaccine candidate that uses recombinant BCG strains to secrete pore-forming listeriolysin, improving its ability to stimulate CD8 T cells. This could lead to better protection against M. tuberculosis infection and potentially halve the estimated 2050 global TB cases.
A simplified regimen of twice-weekly isoniazid preventive therapy for six months or rifampicin and pyrazinamide for two months was found to be effective in preventing active tuberculosis in HIV-infected individuals. Higher compliance with treatment was observed among those who received the shorter course of treatment.
A two-month course of therapy is an effective alternative to the year-long regimen for preventing active tuberculosis in HIV-infected individuals. The study found that fewer deaths occurred among patients in the two-drug arm, with improved treatment compliance compared to the one-drug arm.
Researchers found that using rapid diagnostic methods for M. tuberculosis can decrease diagnosis time from 38.5 to 23 days, time to therapy from 6.6 to 2.0 days, and mortality by 22-33%. This also reduces healthcare costs per patient.
Researchers discovered identical DNA fingerprints in bacterial cultures from two TB patients who were bronchoscoped at the same hospital. The study emphasizes the importance of maintaining TB DNA fingerprint registries to identify unsuspected transmission modes.
Researchers have created an efficient method to study Mycobacterium tuberculosis (TB) using transposon mutagenesis, allowing them to examine the effect of individual gene mutations on the bacteria's ability to grow or cause disease. This breakthrough enables the development of new drug targets and potential vaccine candidates.
Tuberculosis bacteria use the C2a protein to lure macrophages to their death, a strategy that makes them effective pathogens. Understanding this mechanism may lead to the development of a novel vaccine to prevent tuberculosis.
Researchers found that HIV-positive patients living in the eastern United States are at a higher risk of developing tuberculosis, particularly if they have low levels of CD4 cells. The study also revealed that nearly 25% of those diagnosed with TB died from the disease.
Researchers at Johns Hopkins have found that spending more time and money on strict drug regimens saves money in the long run. The cost-effective strategy, called directly observed therapy (DOT), cures more people sooner and decreases the risk of developing TB germs resistant to treatment.